Efeitos do tratamento quimioterápico e hormonioterápico sobre biomarcadores de lesão cardíaca e estresse oxidativo em mulheres com câncer de mama

• Autor(a) principal: Silva, Fabrício Bragança da
• Data de Publicação: 2014
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Espírito Santo (riUfes)
• Texto Completo: http://repositorio.ufes.br/handle/10/7995
• topic: Breast cancer; Cardiovascular diseases; Chemotherapy; Tamoxifen; Oxidative stress; Cardiac injury; Biomarkers; Câncer de mama; Doenças cardiovasculares; Quimioterapia; Tamoxifeno; Estresse oxidativo; Lesão cardíaca; Biomarcadores; Fisiologia; 612

The increase in deaths from cardiovascular disease in women submitted to antineoplastic treatments for breast cancer is a fact observed in many works and is most often associated with cardiotoxic effects of chemotherapy. Although not well understood, it is believed that the cardiotoxicity of chemotherapeutic agents are associated with the increase in oxidative stress. The aim of the present study was to assess the effects of the treatments against breast cancer on biomarkers of cardiac injury and oxidative stress. Thirty women were monitored for one year and divided according to the therapeutic protocol: women subjected to hormone therapy with tamoxifen (Tam group, n = 10), women treated with chemotherapy (chemo group, n = 10), and women treated with chemotherapy followed by hormone therapy with tamoxifen (Chemo+Tam group, n = 10). Blood samples were collected in three moments, before initiation of treatment and after six, and twelve months for the analysis of cardiac troponin I (cTnI), advanced oxidation protein products (AOPP) and plasma activity of the antioxidant enzyme glutathione peroxidase (GPx). We observe that women in the Chemo group showed increased levels of cTnI and AOPP and lower plasma activity of GPx when compared to Tam and Chemo + Tam groups. These data reinforce that oxidative stress may play a significant role in the development of cardiovascular diseases after chemotherapy treatment and highlights a cardioprotective effect of hormone therapy with tamoxifen. Furthermore, accumulated scientific evidence supports the adoption of more effective public policies in monitoring and treatment of the most important causes of morbidity and mortality in the population: cancer and cardiovascular disease.